Collins, P W <br/><br/>
Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.  [electronic resource] 

 -  Haemophilia : the official journal of the World Federation of Hemophilia  Jan 2018 
 - 104-112 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1365-2516 
<br/><br/><label>Standard No.: </label>10.1111/hae.13324  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Area Under Curve<br/>Blood Coagulation Factor Inhibitors--blood<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Factor IX--adverse effects<br/>Half-Life<br/>Headache--etiology<br/>Hemophilia B--drug therapy<br/>Hemorrhage--prevention & control<br/>Humans<br/>Male<br/>ROC Curve<br/>Recombinant Proteins--pharmacokinetics<br/>Severity of Illness Index<br/>Treatment Outcome<br/>Young Adult